Kirin's North American Expansion: Jamieson Acquisition Drives Health Science Growth
Kirin Holdings' acquisition of Jamieson Wellness for C$2.5bn marks its third major health M&A in three years, targeting North America as its health science division achieves profitability. This strategic move aims to leverage proprietary ingredients and consolidate its position in the global supplement market.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Kirin Holdings has completed its third significant health and wellness acquisition in three years, purchasing Canada-based Jamieson Wellness for C$2.5bn (US$1.78bn). This follows the 2023 acquisition of Blackmores and the 2024 acquisition of FANCL. The strategic move into North America, initiated with a scouting period since 2020, coincides with Kirin's health science business reporting its first profitable year in FY2025, reversing a JPY10.9bn deficit into an JPY11.1bn profit. Kirin's President and COO, Takeshi Minakata, identified North America as a critical hub for innovation and the world's largest market for health foods, making it a priority for expansion.
Kirin's health science revenue reached JPY251.4bn (US$1.6bn) in FY25, a 43.4% year-on-year increase, driven substantially by FANCL's JPY112.6bn and Blackmores' JPY70.2bn contributions. The company's Q2 FY2026 results further demonstrate momentum, with health science revenue growing 1.3% to JPY128.8bn and normalized operating profit up 20.8% to JPY10.4bn. Jamieson Wellness, with C$822.1m (US$589.9m) in revenue last year and operations in over 50 countries, derives approximately 65% of its sales from North America, providing Kirin a strong foothold in the region.
The acquisition also facilitates synergistic opportunities. Kirin plans to integrate its proprietary functional ingredients, such as the immune-supporting postbiotic LC-Plasma and cognitive health citicoline, into Jamieson's product development pipeline. This strategy mirrors ongoing collaborations with Blackmores, which has already launched products featuring Kirin's ingredients in Taiwan, Australia, and New Zealand. This ingredient-led innovation is critical for expanding product offerings and differentiating portfolio brands.
Kirin has articulated a long-term vision to become a leading health science company in Asia-Pacific by 2035, targeting JPY500bn (US$3.2bn) in revenue and a 15% normalized operating profit margin. The establishment of Kirin Health Science International in April, led by Blackmores CEO Alastair Symington, underscores their commitment to consolidate and grow their B2C health science operations outside Japan.
What this means for United Kingdom
UK brand owners and manufacturers should anticipate increased competition from multinational players like Kirin, particularly in immune health and cognitive support categories. The consolidation of major brands under Kirin's ownership implies larger marketing budgets and aggressive market penetration, potentially compressing margins for smaller, independent brands. Procurement teams must evaluate the availability and pricing of high-demand ingredients, like LC-Plasma, as Kirin's internal usage could create supply constraints. UK regulatory teams must monitor any potential novel food applications for Kirin's proprietary ingredients as they expand into Western markets, which could open new formulation opportunities but also compliance challenges. Brands might consider strategic partnerships or niche ingredient innovation to maintain competitive differentiation.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.